North America Recombinant Protein Therapeutics Cdmo Market Size & Outlook
North America recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
North America recombinant protein therapeutics cdmo market highlights
- The North America recombinant protein therapeutics cdmo market generated a revenue of USD 8,051.6 million in 2023.
- The market is expected to grow at a CAGR of 13.7% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 8,051.6 million |
| Market revenue in 2030 | USD 19,742.6 million |
| Growth rate | 13.7% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, North America region accounted for 38.5% of the global recombinant protein therapeutics cdmo market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 13,871.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.49% in 2023. Horizon Databook has segmented the North America recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
North America dominated the recombinant protein therapeutics CDMO market and accounted for the largest revenue share of 38.5% in 2023. High share of the region is majorly due to the U.S. being established as a global leader in the production of recombinant protein drugs.
The country has a strong research & development infrastructure and a robust biopharmaceutical industry, which has contributed to its prominence in this field. Furthermore, the U.S. has a sophisticated and well-developed manufacturing infrastructure for biopharmaceuticals, including recombinant protein therapeutics.
This infrastructure includes advanced manufacturing technologies, large-scale production facilities, and stringent quality control processes. The regional market growth can be ascribed to the existence of technologically advanced CDMOs and an upsurge in the allocation of grants.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America recombinant protein therapeutics cdmo market size, by country, 2018-2030 (US$M)
North America Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
